Guerbet (GBT) Q3 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 TU earnings summary
22 Oct, 2026Executive summary
9M 2026 revenue €573.8m, down 1.3% at CER and like-for-like; excluding China, revenue grew 1%, with positive contributions from EMEA, the Americas and Asia.
Q3 revenue fell 3.6% at CER and like-for-like, but was stable excluding China; all 2026 financial targets were confirmed.
Financial highlights
9M revenue was down 2.2% reported and 1.3% at CER; the €4.8m negative FX impact was confined to H1 and largely linked to yen depreciation.
Q3 revenue was €194.6m versus €198.7m in Q3 2025; like-for-like revenue fell 3.6% at CER.
Outlook and guidance
FY 2026 revenue target remains stable or showing a slight decrease at CER and like-for-like.
FY 2026 restated EBITDA margin target remains around 8%, including around €35m of Raleigh remediation-plan costs.
FY 2026 free cash flow target remains strongly negative at -€50m to -€70m, reflecting lower restated EBITDA, higher CAPEX and non-recurring restructuring costs.
Latest events from Guerbet
- Near-flat H1 sales masked losses as refinancing and Raleigh recovery remained pivotal.GBT
H1 2026 - H1 2026 revenue stable at CER, with regional contrasts and ongoing transformation costs.GBT
Q2 2026 TU - Q1 2026 revenue grew 2.6% at CER, driven by EMEA and Asia, despite Raleigh site challenges.GBT
Q1 2026 TU - Net loss of €112.7m driven by impairment, with 2026 outlook negatively impacted by Raleigh.GBT
H2 2025 - 2025 revenue fell 3.5% at CER, but EBITDA margin and cash flow outlooks remain positive.GBT
Q4 2025 TU - Q3 2025 marked a return to growth, led by Elucirem™ and LipiodolⓇ momentum.GBT
Q3 2025 TU - Revenue and profitability fell, prompting lower 2025 guidance and a focus on recovery.GBT
H1 2025 - Revenue up 11.8% at CER, EBITDA margin 15.4%, net income €10m, 2024 outlook raised.GBT
H1 2024 - Sales up 9% to €849m, margin above target, net income down, 2025 outlook positive.GBT
H2 2024